Summary

Psoriatic disease, including psoriasis and psoriatic arthritis, is driven by inflammatory and autoimmune pathways. Biologic agents targeting IL-17 and IL-23 are central to current treatment strategies, but their systemic immunomodulatory impact requires further characte-rization.

Method: A prospective study was conducted in 13 biologic-naive patients with moderate-to-severe psoriasis. Systemic inflammation was assessed using C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and neutrophil-to-lymphocyte ratio (NLR), autoimmunity was evaluated by antinuclear antibody (ANA) testing. Measurements were obtained at baseline and after six months of IL-17/IL-23 inhibitor therapy.

Result: At baseline, elevated ANA titers were present in 15.4% of patients, and most demonstrated increased systemic inflammatory markers. Following six months of therapy, ANA positivity was no longer detected, and CRP, ESR, and NLR values decreased significantly.

Conclusions: IL-17/IL-23 blockade in moderate-to-severe psoriasis appears to reduce systemic inflammation and may modulate autoimmune activity. NLR emerges as a simple and informative biomarker of systemic disease burden in this context.

Abbreviation: PsO-psoriasis, PsA-psoriatic arthritis.